Profile: Fred Hassan, pharma titan, gooseberry picker and secret geography geek
This article was originally published in Scrip
Fred Hassan, partner and managing director at Warburg Pincus, was CEO of Schering-Plough until 2009 when it merged with Merck & Co. He then joined Warburg Pincus and was chairman of eye care firm Bausch + Lomb until its sale in 2013. Before joining Schering-Plough in 2003, Mr Hassan was chairman and CEO of Pharmacia, and he previously held senior executive positions at Wyeth and Sandoz.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.